ReviewMolecular & cellular oncology
Long noncoding RNAs in prostate cancer: mechanisms and applications.
Review in Molecular & cellular oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease.Prostate cancer and prostatic diseases · 2021Article
- Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma.Cell death & disease · 2020Article
- Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.International journal of medical sciences · 2020Article
- Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis.Cancer management and research · 2020Article
- Emerging roles of long non-coding RNAs in cancer.Journal of biosciences · 2019Review
- Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.Frontiers in oncology · 2019Review
- Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star.Molecular cancer · 2018Review
- Long Noncoding RNA and Cancer: A New Paradigm.Cancer research · 2017Review
- Oxidative stress in prostate hyperplasia and carcinogenesis.Journal of experimental & clinical cancer research : CR · 2016Review
- Five lncRNAs Associated With Prostate Cancer Prognosis Identified by Coexpression Network Analysis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large proportion of the control of gene expression in humans is mediated by noncoding elements in the genome. Long noncoding RNAs (lncRNAs) have emerged as a new class of pivotal regulatory components, orchestrating extensive cellular processes and connections. LncRNAs play various roles from chromatin modification to alternative splicing and post-transcriptional processing and are involved in almost all aspects of eukaryotic regulation. LncRNA-based mechanisms modulate cell fates during development, and their dysregulation underscores many human disorders, especially cancer, through chromosomal translocation, deletion, and nucleotide expansions. Recent studies demonstrate that multiple prostate cancer risk loci are associated with lncRNAs and that ectopic expression of these transcripts triggers a cascade of cellular events driving tumor initiation and progression. The recent increased rate of discovery of lncRNAs has been leveraged for application in clinical strategies such as novel biomarkers and therapeutic targets. Despite this potential, many issues remain to be addressed in this fast-growing field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.